Emadine is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 08, 2013. Details of Emadine's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5441958 | Ophthalmic compositions comprising emedastine and methods for their use |
Dec, 2013
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Emadine is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Emadine's family patents as well as insights into ongoing legal events on those patents.
Emadine's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Emadine's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 08, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Emadine Generics:
There are no approved generic versions for Emadine as of now.
About Emadine
Emadine is a drug owned by Novartis Pharmaceuticals Corp. It is used for treating allergic conjunctivitis. Emadine uses Emedastine Difumarate as an active ingredient. Emadine was launched by Novartis in 1997.
Approval Date:
Emadine was approved by FDA for market use on 29 December, 1997.
Active Ingredient:
Emadine uses Emedastine Difumarate as the active ingredient. Check out other Drugs and Companies using Emedastine Difumarate ingredient
Treatment:
Emadine is used for treating allergic conjunctivitis.
Dosage:
Emadine is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05% | SOLUTION/DROPS | Discontinued | OPHTHALMIC |